MedPath

Glucagon

Generic Name
Glucagon
Brand Names
Baqsimi, Glucagen, Gvoke, Ogluo
Drug Type
Biotech
CAS Number
16941-32-5
Unique Ingredient Identifier
76LA80IG2G
Background

Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia. Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.

Glucagon was granted FDA approval on 14 November 1960.

Indication

Glucagon is indicated as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.

Associated Conditions
Severe Hypoglycemia
Clinical Trials
Related News

A Study of Nasal Glucagon in Participants With a Common Cold

Phase 1
Completed
Conditions
Common Cold
Interventions
First Posted Date
2016-05-19
Last Posted Date
2019-09-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
36
Registration Number
NCT02778100
Locations
🇨🇦

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mount-Royal, Quebec, Canada

A Study of Glucagon Administered in Different Forms and Routes to Healthy Adults

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2016-05-19
Last Posted Date
2019-09-19
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
16
Registration Number
NCT02778113
Locations
🇨🇦

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mount-Royal, Quebec, Canada

In Vivo Assessment of Cellular Metabolism in Humans

Phase 1
Completed
Conditions
Normal Cellular Metabolism
Interventions
First Posted Date
2016-04-22
Last Posted Date
2022-08-03
Lead Sponsor
K. Sreekumaran Nair
Target Recruit Count
17
Registration Number
NCT02748369
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Assessment of Intranasal Glucagon on Endogenous Glucose Production

Phase 1
Completed
Conditions
Diabetes
Interventions
Drug: Intranasal placebo
First Posted Date
2016-04-15
Last Posted Date
2016-04-15
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
10
Registration Number
NCT02740829

The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas

Not Applicable
Terminated
Conditions
Diabetes Mellitus Type 1
Interventions
Device: iPhone bionic pancreas
Device: iLet bionic pancreas
Device: Contact Detach infusion set
Device: iLet infusion set
First Posted Date
2016-03-08
Last Posted Date
2019-11-18
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
20
Registration Number
NCT02701257
Locations
🇺🇸

MGH Diabetes Research Center, Boston, Massachusetts, United States

Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation

Phase 2
Completed
Conditions
Type 1 Diabetes
Interventions
Other: Dual-hormone closed-loop
Device: Dexcom G4 Platinum glucose sensor
Device: Accu Chek Combo insulin pump
First Posted Date
2015-12-10
Last Posted Date
2016-06-10
Lead Sponsor
Institut de Recherches Cliniques de Montreal
Target Recruit Count
10
Registration Number
NCT02626936
Locations
🇨🇦

Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada

Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon

Phase 4
Completed
Conditions
Type 1 Diabetes Mellitus
Interventions
First Posted Date
2015-08-05
Last Posted Date
2017-08-31
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
26
Registration Number
NCT02516150
Locations
🇺🇸

Massachusetts General Hospital Diabetes Research Center, Boston, Massachusetts, United States

Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes

Phase 2
Withdrawn
Conditions
Type 1 Diabetes
Interventions
Other: 6-day intervention with single-hormone closed-loop strategy
Other: 6-day intervention with dual-hormone closed-loop strategy
Other: 6-day intervention with sensor-augmented pump therapy
Device: Continuous Glucose Monitoring System Enlite sensor®, Medtronic
Device: Insulin pump MiniMed® Paradigm® Veo™, Medtronic
First Posted Date
2015-07-03
Last Posted Date
2017-10-27
Lead Sponsor
Institut de Recherches Cliniques de Montreal
Registration Number
NCT02490098
Locations
🇨🇦

Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada

Safety and Efficacy of ZP-Glucagon to Injectable Glucagon for Hypoglycemia

Phase 1
Completed
Conditions
Hypoglycemia
Interventions
First Posted Date
2015-06-02
Last Posted Date
2016-08-16
Lead Sponsor
Zosano Pharma Corporation
Target Recruit Count
16
Registration Number
NCT02459938
Locations
🇦🇺

Nucleus Network, Melbourne, Victoria, Australia

G-Pen™ for Hypoglycemia Rescue in T1D Patients

Phase 2
Completed
Conditions
Hypoglycemia
Interventions
First Posted Date
2015-04-22
Last Posted Date
2017-07-07
Lead Sponsor
Xeris Pharmaceuticals
Target Recruit Count
7
Registration Number
NCT02423980
Locations
🇺🇸

Diablo Clinical Research, Inc., Walnut Creek, California, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy